Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
OtherArticle

Development of a selective and high affinity radioligand, [3H]VU6013720, for the M4 muscarinic receptor

Aidong Qi, Haley E Kling, Natasha Billard, Alice L Rodriguez, Li Peng, Jonathan W Dickerson, Julie L Engers, Aaron M Bender, Mark S Moehle, Craig W. Lindsley, Jerri M Rook and Colleen M. Niswender
Molecular Pharmacology August 18, 2023, MOLPHARM-AR-2022-000643; DOI: https://doi.org/10.1124/molpharm.122.000643
Aidong Qi
1Vanderbilt University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haley E Kling
1Vanderbilt University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natasha Billard
1Vanderbilt University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice L Rodriguez
1Vanderbilt University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alice L Rodriguez
Li Peng
1Vanderbilt University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan W Dickerson
1Vanderbilt University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie L Engers
1Vanderbilt University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aaron M Bender
1Vanderbilt University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark S Moehle
2University of the Florida, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig W. Lindsley
3Pharmacology, Vanderbilt, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerri M Rook
1Vanderbilt University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colleen M. Niswender
1Vanderbilt University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Colleen M. Niswender
  • For correspondence: colleen.niswender@vanderbilt.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

M4 muscarinic receptors are highly expressed in the striatum and cortex, brain regions that are involved in diseases such as Parkinson's disease, schizophrenia, and dystonia. Despite potential therapeutic advantages of specifically targeting the M4 receptor, it has been historically challenging to develop highly selective ligands, resulting in undesired off-target activity at other members of the muscarinic receptor family. Recently, we have reported first-in-class, potent, and selective M4 receptor antagonists. As an extension of that work, we now report the development and characterization of a radiolabeled M4 receptor antagonist, [3H]VU6013720, with high affinity (pKd of 9.5 {plus minus} 0.2 at rat M4, 9.7 at mouse M4, and 10 {plus minus} 0.1 at human M4 with atropine to define nonspecific binding) and selectivity (80-fold over M2 and >1,000 fold over M1, M3 and M5) for the M4 receptor versus the other muscarinic subtypes. Binding assays using this radioligand in rodent brain tissues demonstrate loss of specific binding in Chrm4 knockout animals. Dissociation kinetics experiments with various muscarinic ligands show differential effects on the dissociation of [3H]VU6013720 from M4 receptors, suggesting a binding site that is overlapping but may be distinct from the orthosteric site. Overall, these results demonstrate that [3H]VU6013720 is the first highly selective antagonist radioligand for the M4 receptor, representing a useful tool for studying the basic biology of M4 as well for the support of M4 receptor-based drug discovery.

Significance Statement This manuscript describes the development and characterization of a novel muscarinic acetylcholine subtype 4 receptor antagonist radioligand, [3H]VU6013720. This ligand binds to or overlaps with the acetylcholine binding site, providing a highly selective radioligand for the M4 receptor that can be used to quantify M4 protein expression in vivo and probe the selective interactions of acetylcholine with M4 versus the other members of the muscarinic receptor family.

  • Acetylcholine receptors
  • muscarinic receptors
  • Parkinson's Disease
  • schizophrenia
  • Copyright © 2023 American Society for Pharmacology and Experimental Therapeutics
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 104 (4)
Molecular Pharmacology
Vol. 104, Issue 4
1 Oct 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Development of a selective and high affinity radioligand, [3H]VU6013720, for the M4 muscarinic receptor
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherArticle

Development of the M4 antagonist radioligand, [3H]VU6013720

Aidong Qi, Haley E Kling, Natasha Billard, Alice L Rodriguez, Li Peng, Jonathan W Dickerson, Julie L Engers, Aaron M Bender, Mark S Moehle, Craig W. Lindsley, Jerri M Rook and Colleen M. Niswender
Molecular Pharmacology August 18, 2023, MOLPHARM-AR-2022-000643; DOI: https://doi.org/10.1124/molpharm.122.000643

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherArticle

Development of the M4 antagonist radioligand, [3H]VU6013720

Aidong Qi, Haley E Kling, Natasha Billard, Alice L Rodriguez, Li Peng, Jonathan W Dickerson, Julie L Engers, Aaron M Bender, Mark S Moehle, Craig W. Lindsley, Jerri M Rook and Colleen M. Niswender
Molecular Pharmacology August 18, 2023, MOLPHARM-AR-2022-000643; DOI: https://doi.org/10.1124/molpharm.122.000643
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Analgesic Effects and Mechanisms of Licochalcones
  • Induced Fit Ligand Binding to CYP3A4
  • Englerin A Inhibits T-Type Channels
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics